Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
Avtorji:ID Omersa, Daniel (Avtor)
ID Čufer, Tanja (Avtor)
ID Marčun, Robert (Avtor)
ID Lainščak, Mitja (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.degruyter.com/view/j/raon.ahead-of-print/raon-2016-0037/raon-2016-0037.xml
Opis: Prost dostop
 
.pdf PDF - Predstavitvena datoteka, prenos (437,07 KB)
MD5: 1606A31CE61078C5507648D91D59D048
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Background. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains an important cause of cancer death worldwide. Platinum-based chemotherapy (PBC) for NSCLC can modify outcome while the risk of cardiotoxicity remains poorly researched. We aimed to evaluate the incidence and severity of cardiac injury during PBC in patients with NSCLC and to identify patients at risk. Methods. This was a single-centre, prospective, observational study of patients with early and advanced stage NSCLC referred for PBC. In addition to standard care, patients were examined and evaluated for cardiotoxicity before the first dose (visit 1), at the last dose (visit 2) and 6 months after the last dose of PBC (visit 3). Cardiotoxicity (at visit 2 and 3) was defined as increase in the ultrasensitive troponin T, N-terminal pro-B type natriuretic peptide or decrease in left ventricular ejection fraction (LVEF). Results. Overall, 41 patients (mean age 61 +/- 9; 54% men; 68% advanced lung cancer) were included. The median number of PBC cycles was 4. During the study period, there were no incidents of heart failure, and 3 deaths caused by tumour progression were recorded. The mean values of biomarkers and LVEF did not change significantly (p > 0.20). However, 10 (25%) had cardiotoxicity which was independently associated with a history of ischemic heart disease (p = 0.026). Conclusions. In NSCLC, cardiac assessment and lifestyle modifications may be pursued in patients with a history of cardiac disease and in patients with longer life expectancy.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.03.2017
Založnik:Association of Radiology and Oncology
Leto izida:2017
Št. strani:str. 15-22, III
Številčenje:Vol. 51, ǂno.ǂ1
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18905 Novo okno
UDK:616.2
ISSN pri članku:1318-2099
COBISS.SI-ID:765091 Novo okno
Avtorske pravice:by Authors
Opomba:Soavtorji: Tanja Čufer, Robert Marčun, Mitja Lainščak;
Datum objave v DiRROS:10.05.2024
Število ogledov:638
Število prenosov:389
Metapodatki:XML DC-XML DC-RDF
:
OMERSA, Daniel, ČUFER, Tanja, MARČUN, Robert in LAINŠČAK, Mitja, 2017, Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Radiology and oncology [na spletu]. 2017. Vol. 51, no. 1, p. 15–22, iii. [Dostopano 18 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18905
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Nazaj